Background: Homeobox genes murine Rhox5 and human RHOXF1 are expressed in early embryonic stages and then mostly restricted to germline tissues in normal adult, yet they are aberrantly expressed in cancer cells in vitro and in vivo . Here we study the epigenetic regulation and potential functions of Rhox5 gene.
Background
The reproductive homeobox on X-chromosome (Rhox ) gene cluster in mouse contains 33 known genes [1] , and three members of this gene family (Rhox2, Rhox4b and Rhox5 ) are crucial for self-renewal and differentiation of embryonic stem (ES) cells [2] [3] [4] . The founding member of Rhox gene cluster, Rhox5 (formerly pem), is expressed in early embryos and ES cells [5] [6] [7] , embryonic carcinoma (EC) cells, and primordial and pre-muscle stem cells [8] . Intriguingly, Rhox5 is predominantly expressed in female blastocysts from the paternally inherited X chromosome [7] , yet the paternal copy is silent in placenta cells [9] . In adult mice, Rhox5 expression is restricted to germline tissues in both male and female and is silenced in most somatic tissues [1, 10, 11] . Rhox5 is expressed from its two promoters, a distal promoter (Pd) and a proximal promoter (Pp), that give rise to transcripts with different 5'-ends encoding the same protein. The transcription from Pp depends on both androgen receptor and androgen [10] . Rhox5 plays an essential role in self-renewal and differentiation of ES cells. It has been shown that Rhox5 over-expression is able to maintain murine ES cells in a pluripotent state in a leukemia inhibitory factor-independent manner [6] , and can also block ES cell differentiation [3, 11] . It promotes differentiation and survival of germ cells in germline tissues [10] . Targeted disruption of Rhox5 increases male germ cell apoptosis and reduces sperm production, sperm motility, and fertility [12] .
Rhox5 is expressed not only in established cancer cell lines [13] [14] [15] , but also in cancers in vivo, e.g., adenomas and carcinomas in the APC Min/+ mice and large intestine tumors of Msh2-deficient mice conditionally expressing K-ras (V12) [16, 17] . The Pd promoter was regarded as the promoter directing the aberrant expression in tumor cells [10] .
Rhox5 may exert important functions in cancer based on the following evidence. First, partners for Rhox5 include: menin, a tumor suppressor [18] , prosaposin, a multifunctional protein [19] , and the cell division cycle 37 (Cdc37) homolog protein [20] . Second, Rhox5 also mediates transcriptional repression of the netrin-1 receptor gene Unc5c, a tumor suppressor in colorectal cancer [21] . Third, Rhox5 gene Pd activity in tumor cells requires Ras signaling [22] . Fourth, in a colon adenoma model induced by conditional activation of K-ras V12 in Msh2 knockout mice, Rhox5 is one of three genes significantly up-regulated [17] . Finally, Rhox5 renders tumor cells resistant to apoptotic cell death induced by anticancer therapies [23] . In addition, it may play a role in cancer initiating cells (or cancer stem [CS] cells) [24] . CS cells are cancer cells that possess characteristics associated with normal stem cells. They have the ability to give rise to all cell types found in a particular tumor. It is possible that ES and CS cells share some key regulatory genes that are tightly regulated by similar epigenetic mechanisms.
While there are a total of 33 known Rhox genes clustered in the X chromosome in mouse [1] , only two RHOX genes have been characterized in humans: RHOXF1 (originally called OTEX and hPEPP1) and RHOXF2A (originally hPEPP2) [25, 26] . While there is no human homolog of mouse Rhox5, human RHOXF1 is closest to murine Rhox5 in terms of chromosomal location of the gene, tissue expression profiles, and potential functions. RHOXF1 is expressed at relatively high levels in human ES cells and adult germline stem cells [27] . It is expressed in human colorectal cancer and testicular seminoma in vivo [28, 29] , as well as in some cancer cell lines [15, 26] . Therefore, it is possible that Rhox5 and RhoxF1 may have comparable functions despite low sequence conservation and therefore they may be considered orthologues.
DNA methylation regulates gene expression in normal mammalian development [30, 31] . In cancer, aberrant promoter hypermethylation plays a major role in transcriptional silencing of critical growth regulators such as tumor suppressor genes [32, 33] , while aberrant promoter hypomethylation upregulates germline genes (such as Rhox5 ) that are normally expressed in embryo stages and stem cells yet silenced in all or most somatic tissues [34, 35] . Histone modifications together with DNA methylation in the chromatin regulate many regulatory genes [36, 37] . All known acetylations of histones are correlated with transcriptional activation [38] . Histone methylations at lysine and arginine residues are another class of epigenetic marks [39, 40] . A recent highresolution profiling study in the human genome indicated that H3K4 trimethylation and the monomethylations of H3K9, H3K27, H3K79, H4K20 and H2BK5 are linked to gene activation, whereas trimethylations of H3K27, H3K9 and H3K79 are linked to repression [40] . In addition, a "bivalent domain" (repressive mark H3K27me3 and permissive mark H3K4me2/me3) marks key developmental genes in ES cells [41, 42] . This chromatin bivalent domain in stem/progenitor cells predisposes tumor suppressor genes to DNA hypermethylation and heritable silencing [43] [44] [45] .
RHOX5 may be regulated by epigenetic mechanisms. First, DNA methylation regulates long-range silencing of Rhox gene cluster including Rhox5 during the postimplantation development of mice [46] . Second, Rhox5 could be upregulated in ES cells and embryonic fibroblast cells by inactivation of DNA methyltransferase genes [46, 47] , or in ES cells null for linker histone H1 [48] . While this paper was under revision, Wilkinson, MacLean, and coworkers showed that the Rhox gene cluster is imprinted and regulated by histone H1 and DNA methylation in ES cells [9] . Third, Rhox5 is one of the X-linked cancer-germline (CG) genes, many of which are regulated by DNA methylation [14, 35, 49] . Finally, we have demonstrated that epigenetic drugs could upregulate Rhox5 in cancer cells through enrichment of active histone marks in the promoter region preferentially with DNA demethylation [15] .
We and our collaborators have previously investigated epigenetic regulation of genes in normal development and cancer [15, 35, [50] [51] [52] . In this study, we have confirmed that Rhox5 is expressed in ES cells, EC cells, and cancer cells. We found that Rhox5 is expressed in side population (SP) cells that enrich for cancer stem/progenitor cells. We have examined the epigenetic marks in the promoter region, including both DNA methylation and histone acetylation (H3ac, H4ac and H3K9ac) and methylation (H3K4me2, H3K9me2 and H3K27me3), and related them to levels of expression in various cells types. We showed that epigenetic drugs could induce differentiation of F9 teratocarcinoma cells, but not SP cells, with Rhox5 upregulation and concurrent epigenetic changes. Finally, we demonstrated that Rhox5 gene knockdown by small hairpin RNA (shRNA) in CT26 colon cancer cells resulted in reduced tumor cell migration and cell proliferation in vitro and attenuated tumor growth in vivo .
Results

Expression of Rhox5 gene in ES cells, somatic cells and cancer cells
Rhox5 gene transcription is controlled by dual promoters, Pd and Pp, producing mRNAs with different 5' ends yet encoding the same protein ( Figure 1A ). We initially examined Rhox5 expression in cancer cells as well as in ES cells and germline tissues. As shown in Table 1 , Rhox5 mRNA was detected in all 26 cancer cell lines tested. These cancer lines were derived from 12 different tissues. Two cancer cell lines (EMT6 and P815) generated faint bands after 35 cycles of PCR following reverse transcription (RT) ( Figure 1B ). In contrast, another cancer-germline gene, P1A, which we studied previously, was expressed in a much smaller fraction of cancer cell lines. We then quantified Rhox5 mRNA from representative tissues or cells by RT-qPCR ( Figure 1C ). Testis tissue expressing Rhox5 mRNA was utilized as a positive control. ES and F9 EC cells expressed low levels of Rhox5 mRNA. Normal somatic cells such as mononucleocytes (MNC) did not express Rhox5 mRNA. Rhox5 expression in cancer cells varied over a wide range, with high levels in CT26 and MC38 cells and extremely low levels in EMT6 and P815 cells.
We next analyzed promoter-specific transcription from both Pd and Pp of Rhox5 gene in selected normal cells and cancer cells by promoter-specific RT-PCR as described previously [15] . As shown in Figure 1D , testis tissue utilized both Pd and Pp for transcription, while ES cells utilized the Pd promoter for transcription. TM4 Sertoli cells utilized mainly Pd, consistent with results from a previous study [53] . Among the selected group of cancer cells, CT26, MC38, and 4T1 cells utilized both Pd and Pp for transcription. Rhox5 mRNA was barely detectable in EMT6 and P815 cells.
We further confirmed gene expression at the protein level by Western blot analysis ( Figure 1E ). Both germline tissues (testis and ovary) and selected cancer cells expressed Rhox5 protein (~30 kDa). In contrast, Rhox5 protein was below the level of detection in EMT6 and P815 cancer cells. These results were consistent with those obtained by RT-PCR.
RHOXF1 expression in human primary colorectal cancers
We wished to confirm if RHOXF1 is expressed in human colorectal cancers, as reported by gene expression profiling [28] . We collected eight matched sets of specimens from patients with metastatic colorectal cancer. These tissues represented liver metastasis and matched normal liver tissues from eight patients. Total RNA was purified from these tissues, and the amounts of RHOXF1 mRNA were quantified by RT-qPCR ( Figure  2 ). RHOXF1 mRNA was expressed in the normal liver tissues (N), ranging from 122 to 558 copies relative to 1.0E6 copies of β-actin mRNA. In the tumor tissues (T), RHOXF1 mRNA was also expressed in 7 out of 8 patients, ranging from 15 to 310 copies of mRNA.
Correlation of Rhox 5 gene expression to the histone epigenetic marks in the promoter region of the gene
We sought to find a correlation between Rhox5 gene expression and its epigenetic marks in the promoter region ( Table 2 ). Initially we examined histone modifications in ES and other cells by ChIP assays. In ES cells, there was a low level of H3K4me2 and higher levels of H3K27me3 and H3K9me2 marks on ChIP-1 region (Figure 3A) . In Pd region (ChIP-2 region), the pattern was similar. This pattern of histone marks would correlate with the low level of expression seen in ES cells. In gene-silenced MNC and mammary epithelial cells, as well as P815 cancer cells with extremely low level of Rhox5 mRNA, they revealed high levels of H3K9me2 together with low levels of H3K27me3. The active marks were either undetectable or barely detectable ( Figure 3A and Additional File 1). Interestingly, we did not detect H3K4me2, H3K27me3, and H3K9me2 marks on Rhox5 Pd region in 4T1 cells, although a low level of mRNA was transcribed from Pd in these cells (Additional File 1).
We chose to compare the histone marks in two cancer cell lines with either the highest (CT26) or the lowest (EMT6) Rhox5 expression ( Figure 3B & C). The active marks (H3ac, H4ac, H3K9ac and H3K4me2) are high in CT26 cells, and very low in EMT6 cells. Interestingly, we detected relative high levels of repressive marks (H3K9me2 and H3K27me3) in both CT26 and EMT6 cells.
We have also paid attention to the "bivalent domain" chromatin structure in the promoter region. The H3 K4me2 and K27me3 bivalent marks exist not only in undifferentiated ES cells, but also in germline-tissue derived somatic cells (TM4) and some cancer cells (MOSEC, CT26 and MC38).
Strong correlation of promoter DNA methylation with Rhox 5 gene expression
We wished to determine DNA methylation status in the promoters of Rhox5 gene in the same set of cell types. Both Pd and Pp promoters of the gene are CpG-poor and contain no CpG islands (GenBank accession: AF410462) [54] . Specific primers were selected to amplify bisulfite-treated genomic DNA from ten lines of cells including ES cells, somatic cells, and cancer cells. These primers covered DNA segments in the Pd, Pp, and translation start site (TSS) regions (BS-1, BS-2 and BS-3 regions, respectively), covering four CpG dinucleotides each (see Figure 1A ). As shown in Figure 4 (A & B), both ChIP-1 (Pd) and TSS regions were relatively hypermethylated in ES cells. As Rhox5 is expressed at a low level from Pd in ES cells, our results suggested that DNA hypermethylation and a moderately repressive pattern of histone epigenetic marks together dictated a low level of Rhox5 expression. TM4 and MOSEC cells had similar epigenetic patterns as ES cells, and this also correlated with low level of Rhox5 expression. For CT26 and MC38 cells that express high levels of Rhox5 gene, hypomethylated DNA was found in the promoter regions. Data from additional normal and cancer cells were presented in Additional File 2. The percentage of CpG methylation in the Pd region correlated quite well with the levels of Pd mRNA expression in the cells ( Figure 4B ). 
represents a strong while "-/+" very weak and "-" undetectable signals of cDNA amplification after 35 cycles of PCR following reverse transcription (RT). The status of P1A expression in some cancer cell lines has been reported in our previous study [35] .
Differentiation of F9 EC cells induced by epigenetic agents resulted in significant changes of histone marks
A distinct characteristic of genes marked by a bivalent domain is that these genes can change expression levels rapidly during ES differentiation as bivalent marks are resolved to monovalent marks (H3K4me2 or H3K27me3 only), remain bivalent, or disappear altogether [41, 42, 55] . As a result we sought to study changing patterns of histone epigenetic marks during EC differentiation. The F9 EC cells can be induced to differentiate with upregulation of Rhox5 mRNA by retinoic acid (RA), RA plus cAMP, or valproic acid. All these agents exhibit properties of epigenetic modulators [8, 56, 57] . The HDAC inhibitor MS-275 can induce p21-dependent growth arrest and differentiation of human leukemia cells at lower doses [58] . We demonstrated that both MS-275 and RA treatment induced Rhox5 mRNA 3-fold by 72 h, and RA plus cAMP could induce Rhox5 20-25fold in 5 days ( Figure 5A ). These differentiated cells displayed dramatically reduced tumorigenicity in nude mice (Additional File 3). In undifferentiated F9 EC cells, the Pd promoter was marked with low levels of K4me2, but higher levels of K27me3 and K9me2 ( Figure 5B ). Upon induced differentiation by either drug, K27me3 disappeared and K4me2 was reduced (p < 0.05), while K9me2 was not significantly affected.
Rhox5 induction in silenced cancer cells by epigenetic drugs via increased permissive and decreased repressive marks
We sought to study the dynamic changes of histone marks along with Rhox5 gene induction in cancer cells treated with DAC or MS-275. CA07/A, EMT6 and P815 cancer cells express very low levels of Rhox5 mRNA ( Figure 1 and Table 1 ). Upon treatment with decitabine (DAC) or MS-275, Rhox5 mRNA was significantly upregulated, ranging from 40 to 3000-fold ( Figure 5C ). We then analyzed the histone marks in the Pd in cancer cells without or with drug treatment ( Figure 5D ). In mock-treated EMT6 and P815 cancer cells, there were elevated levels of H3K9me2, very low levels of H3K27me3, and undetectable levels of H3K4me2. After drug treatment, significant induction in H3K4me2 and reduction in H3K9me2 was observed, yet H3K27me3 remained low or reduced.
Rhox5 was expressed in SP and NSP of cancer cells with bivalent histone marks
We next examined whether Rhox5 was expressed in cancer stem (CS)/progenitor cells and whether there was an associated bivalent chromatin pattern. The SP from primary cancers and cancer cell lines has been shown to be enriched for CS/progenitor cells [59] . Hoechst 33342 dye exclusion was performed with verapamil as a specific inhibitor of H33342 transport in order to identify SP. We initially chose CT26 colorectal cancer cells and showed that there was a small fraction of SP (~1%) and that Rhox5 was expressed in both SP and NSP (data not shown). Due to the number of SP cells needed to properly perform the ChIP assays, it was difficult to obtain sufficient SP cells from this colorectal cancer cell line. Thus we utilized ovarian cancer cells because ovarian cancer cells contain a relatively large SP that is enriched for CS/progenitor cells [60] . Indeed we showed that the MOSEC ovarian cancer cell line contained 9.7% of SP and that this population could be blocked by verapamil ( Figure 6A ). RT-qPCR demonstrated that SP expressed Rhox5 mRNA about 3-fold higher than NSP from MOSEC cancer cells ( Figure 6B ). We examined the possibility of Figure 6B ). We also examined two key histone marks (K4me2 and K27me3, the bivalent marks) and found that the Pd promoter was marked by both K4me2 and K27me3 in both SP and NSP from MOSEC cells. As expected, MS-275 treatment did little to change the pattern of these two histone epigenetic marks in SP cells ( Figure 6C ).
Rhox5 knockdown attenuated cell proliferation and cell migration in vitro and tumor growth in vivo
Little is known concerning Rhox5 function in cancer cells. Therefore we wished to explore the functions of Rhox5 in cancer cells. We selected a colon cancer model (CT26) for Rhox5 functional analyses since our initial results indicated that CT26 cells express a high level of Rhox5 mRNA. We used lentivirus-mediated shRNA against Rhox5 to knockdown the expression of this gene. As shown in Figure 7A , shRNA clone 49 demonstrated a higher knockdown efficiency than clone 48 (80% versus 50%) as determined by RT-qPCR. Western blot analysis confirmed that Rhox5 protein was greatly reduced in clone 49 ( Figure 7B ). We chose clone 49 for further characterization in vitro and in vivo . Cell proliferation was significantly decreased at 72 and 96 h following knockdown compared to the parental CT26 cells and corresponding control lentiviral vector transduced (CTV) CT26 cells (p < 0.05) ( Figure 7C ). Cell migration ability in clone 49 cells was also significantly reduced (p < 0.05; compared to CT26 and CTV, respectively) ( Figure 7D ). We further examined the property of tumor growth from shRNA knockdown and parental CT26 cells in a subcutaneous tumor model in athymic nude mice. Tumor growth was slower over time in mice inoculated with clone 49 compared to those with parental CT26 cancer cells or CTV CT26 cells. At the time of sacrifice (day 19), both tumor volumes and tumor weights were significantly reduced in the clone 49 group compared to the two control groups (p < 0.05) ( Figure 7E ).
Discussion
The Rhox gene cluster is essential for development, and three members (Rhox2, Rhox4 and Rhox5 ) have important functions for pluripotency of ES cells. In a recent study, it has been demonstrated that Rhox2 and Rhox4 genes, both expressed at low levels in ES cells, are marked by neither K4 nor K27 trimethylation of histone H3 in ES cells [61] . This suggests that DNA methylation is one of the major repressive mechanisms for those genes that lack both H3 K4/K27 trimethylations. Previous studies suggest that DNA methylation is involved in Rhox5 gene regulation, yet histone modifications around the promoter region of the gene in correlation to gene expression have not been examined.
In this study, we undertook the task of analyzing the epigenetic marks in the Rhox5 gene promoter region, and we related these modifications to Rhox5 expression levels in ES cells, germline-tissue-derived Sertoli cells, cancer cells, and cancer stem/progenitor cells, as well as Rhox5 -silenced somatic cells. We had three main goals in mind. First, we wanted to examine both DNA methylation patterns and histone marks around the promoter region to determine if the epigenetic patterns would correlate with Rhox5 expression in those cells. Second, we wish to examine whether the "bivalent domain" epigenetic feature originally identified in key developmental genes in ES cells also existed in the Rhox5 gene in both ES cells and other types of cells such as cancer stem cells. Finally, since Rhox5 is expressed in most, if not all, of the cancer cell lines and in colorectal cancer in vivo, it was of great interest to begin to uncover its potential function in cancer.
The general conclusion from our current study is that the sum of both active and repressive epigenetic marks together dictates the levels of Rhox5 mRNA expression in a particular cell type or cell line. DNA hypermethylation together with repressive histone modifications dictate the silencing or extreme reduction in Rhox5 expression in normal mononucleocytes (MNC) or EMT6 cancer cells. In cells expressing low levels of Rhox5 such as ES cells, F9 cells, and TM4 cells, DNA is moderately methylated, and the histone epigenetic marks profile shifted to a more neutral state. These cells displayed both active marks and repressive marks, even though the exact marks and levels of these marks varied from one cell type to another. The existence of a "bivalent domain" represents such an epigenetic feature in these cells. In cells (CT26 and MC38) with high levels of Rhox5 expression, DNA is hypomethylated, and the active histone marks are also elevated, consistent with high levels of Rhox5 mRNA. Surprisingly, we also detected high levels of repressive histone marks.
We found the "bivalent domain" chromatin epigenetic structure in the Rhox5 promoter not only in ES cells and SP cells enriched for cancer stem/progenitor cells, but also in cancer cells and fully differentiated germline tissue-derived somatic Sertoli cells. Our study is not the first to show that the bivalent chromatin signature is present in somatic cells. Roh et al. have shown that about 59% of gene promoters studied in primary human T cells contain bivalent marks [62] . In the human foreskin fibroblast BJ cell line, bivalent marks exist in some lineage specific genes [63] . In cancer cells, SFRP and GATA genes are marked by a bivalent chromatin domain, and the authors defined this as a "stem cell-like chromatin structure" [60] . For Rhox5, we also found this stem cell-like chromatin structure in three cancer cell lines (CT26, MC38 and MOSEC). Populations of cancer cells are heterogeneous and contain only a small number of cancer stem cells that possess the capacity to maintain self-renewal and undifferentiated status. We further sorted two cell populations (SP and NSP) from MOSEC cells. Surprisingly, both fractions of cells contain the bivalent domain in the Rhox5 gene promoter.
One of our initial aims was to induce differentiation of CS/progenitor cells by HDAC inhibitors [64] , in order to examine Rhox5 gene expression during differentiation and to explore this as a potential therapeutic approach. F9 EC cells are considered by many to be the malignant stem cells of teratocarcinoma [65] . We have confirmed that F9 cells can be differentiated into "normal cells" by epigenetic drugs such as RA and MS-275. Upon such an induction of differentiation these cells display a benign phenotype as the tumor formation in nude mice was retarded. The Rhox5 gene was upregulated and the bivalent marks disappeared or were greatly reduced. This is consistent with findings by other investigators that a fairly large group of active genes contain neither of the two histone marks [40, 66] . The remodeling of these histone marks in the promoter may be related to the differentiation status and/or particular cell type after induction of differentiation.
When MS-275 was applied to the CS/progenitorenriched SP cells from MOSEC ovarian cancer, it failed to up-regulate Rhox5 and did not reduce the bivalent chromatin pattern in the gene. In this and other studies, SP cells were isolated based on the property of high levels of ABCG2 pump molecule capable of mediating the active efflux of numerous anticancer drugs and the dye Hoechst [59] . These SP cells could mediate the efflux of MS-275 similar to what occurs with other drugs. This might explain why SP cells failed to respond to MS-275-induced cell differentiation.
We showed that Rhox5 knockdown by shRNA in CT26 colon cancer decreased cell migration and cell proliferation in vitro and tumor growth in vivo . This is reminiscent of the previous results that targeted disruption of Rhox5 increased male germ cell apoptosis and reduced sperm production, sperm motility, and fertility [12] . What are the downstream molecules and how does Rhox5 knockdown affect downstream signaling in cancer? One gene directly targeted by Rhox5 is Unc5c, a tumor suppressor frequently silenced by DNA methylation in colon cancer [21, 67] . In CT26 colon cancer cells, Unc5c is not expressed, and Rhox5 knockdown by shRNA did not change Unc5c expression (data not shown). Instead, the attenuated CT26 cancer growth and migration by Rhox5 knockdown may be mediated by Ras-ERK signaling pathway. Evidence for this could be found in a colon adenoma model induced by conditional activation of K-ras V12 in Msh2 knockout mice in which Rhox5 is one of three genes significantly upregulated [17] . Interestingly, P1A, another epigenetically regulated and X-linked cancer-germline gene we have studied previously [35] , was also upregulated in this K-ras V12 /Cre//Msh2tumor model. A recent study showed that ectopic expression of Rhox5 in cancer cells induced a significantly increased extracellular signalregulated kinase (ERK) activity and multiple resistance to various apoptotic pressures [23] . In addition, it has been shown that Ras signaling activates Rhox5 transcription through its Pd promoter [68] . Oncogenic Ras signaling also induces tumor promoting genes and directs epigenetic inactivation of tumor suppressor genes [69, 70] . Another downstream component of the Ras signaling pathway, NF-B, promotes breast cancer cell migration and thus metastasis by inducing chemokine receptor CXCR4 [71] . Therefore, our finding that Rhox5 knockdown attenuated tumor cell growth and cell migration fits a hypothetic Ras tumor promoting signaling pathway in which ERK1/2, NF-B, and Rhox5 function downstream. Further studies will shed more light on Rhox5 function in precancerous lesions and in cancer progression of colon malignancy. In addition, Rhox5 is widely expressed in cancer cells and cancer stem/progenitor cells, and can be selectively induced or suppressed by epigenetic agents. Thus, Rhox5 could serve as an ideal target for therapeutic interventions including shRNA therapy, cancer immunotherapy, and epigenetic therapy.
The closely related human gene RHOXF1 has been shown to be expressed in ES cells and adult germline stem cells, some established cancer lines and in primary metastatic colorectal cancer. Its expression pattern is consistent with potential roles in ES cells, adult tissue stem cells, and possibly cancer stem cells, despite the fact that we know little, if any, of its biological functions. Efforts to elucidate the functions of RHOXF1 in the biology of cancer and reproduction and to explore RHOXF1 as a potential therapeutic target should be undertaken.
Methods
Cell culture and human tissues
Many cancer cell lines have been used in our previous studies [15, 35] . The F9 EC cells were obtained from the American Type Culture Collection (Manassas, VA). In order to maintain F9 undifferentiated status, F9 cells were grown on gelatin-coated tissue culture plates. All cells were cultured in the recommended culture media supplemented with 5% or 10% fetal bovine serum (FBS), plus penicillin and streptomycin.
Undifferentiated mouse ES cells (genotype 129*129, passage 18) were purchased from Open Biosystems (Huntsville, AL). They were used directly for analysis of gene expression, bisulfite sequencing, and ChIP assays.
The specimens of human colorectal cancer and matched normal tissues were collected under the UPCI protocol # 02-077, with consent of the patients.
Flow cytometry
To identify and isolate the side population and non-side population cell fractions, cancer cells were harvested, washed, and suspended at 1.0E6 cells/ml in Hanks balanced salt solution (HBSS) (Invitrogen, Carlsbad, CA) as described [72] . The cells were labeled with Hoechst 33342 (Invitrogen) at a concentration of 5.0 μg/ml in the absence and presence of 50 μM verapamil (Sigma, St. Louis, MO). The labeled cells were incubated for 90 min at 37°C. After washing with HBSS once, the cells were counterstained with 1.0 μg/ml 7-AAD (Becton Dickinson, Franklin Lakes, NJ) to label dead cells. The cells were analyzed by using a MoFlo cell sorter (Beckman Coulter, Fort Collins, CO).
Drug treatment
Rhox5 gene induction was performed by treating cancer cells with 5-aza-2-deoxycytidine (DAC, 2.0 μM for 48 h) or MS-275 (2.0 μM for 72 h) [15] . Cells were plated in 100 mm culture plates to obtain~20% confluence. After overnight incubation, cells were treated daily with drugs at different concentrations for 487 2 h. To induce differentiation, F9 cells were cultured in gelatinized plates in the presence of 0.1 μM retinoic acid (RA) (Sigma) or RA plus 1.0 mM cAMP (Sigma) as described [8] .
RNA isolation, RT-PCR and RT-qPCR
Total RNA purification, RT-PCR, and RT-qPCR were performed as described previously [15] . RT-qPCR was performed with an ABI StepOnePlus real-time PCR system (Applied Biosystems, Foster City, CA). The copy numbers of mRNA were determined with relative quantitation by the comparative Ct method using the software with the machine.
Western blot analysis
Western blot analysis was performed as described [15] . Briefly, protein extract was prepared from tumor cells and from ovary and testis tissues of BALB/c mice. Twenty micrograms of protein was resolved on 12% SDS polyacrylamide gels and transferred to immobilon-P PVDF membrane (Millipore, Billerica, MA). The resulting blots were blocked with 5% nonfat dry milk and probed with antibodies specific for Rhox5 (Abcam, Cambridge, MA) and ß-actin (Sigma).
Isolation of genomic DNA and bisulfite sequencing
Genomic DNA from cell lines was extracted using a QIAamp DNA mini kit (Qiagen, Volencia, CA). DNA from spleen mononucleocytes (MNC) of a BALB/c mouse was extracted using a DNeasy Tissue kit (Qiagen). Bisulfite modification of DNA, subcloning, and sequencing of converted DNA were performed as described [15] .
Chromatin immunoprecipitation (ChIP) assay and realtime PCR
ChIP assays were performed using EZ-ChIP kits (Millipore, Billerica, MA) [15] . The following ChIP-grade antibodies were used: anti-acetyl histone H3 [H3ac] and anti-acetyl histone H4 [H4ac] (Millipore), anti-acetyl histone H3 lysine 9 [H3K9ac], anti-dimethyl histone H3 lysine 4 [H3K4me2], anti-dimethyl histone H3 lysine 9 [H3K9me2], anti-trimethyl histone H3 lysine 27 [H3K27me3], and an isotype control IgG (All from Abcam). In earlier experiments, histone 3 K4, K27, and K9 methylation in the ChIP-1 region was quantified by semi-quantitative PCR gel density analysis. In all later experiments, real-time PCR was used to quantify the amounts of DNA fragment in the ChIP assays. Specific primer sets were designed to amplify Rhox5 gene ChIP-1 (Pd) and ChIP-2 (Pp) regions. Most primer sequences are listed in Additional File 4. For Rhox5 Pd real-time PCR, 2.0 μl of DNA was added to PCR reaction systems using a QuantiTect SYBR Green PCR kit (Qiagen). We performed quantitative PCR data analysis of ChIP assay using a formula described in the User Manual of Cham-pionChIP™ kits (SA Biosciences, Frederick, MD, USA). Briefly, we normalized each ChIP DNA fractions' Ct value to the Input DNA fraction Ct value for the same qPCR Assay (ΔCt) to account for chromatin sample preparation differences. Then we reported ChIP-qPCR results as a "% Input" for characterizing individual experimental samples.
ShRNA-mediated knockdown of Rhox5 gene
Four different lentivirus particles with target shRNA against Rhox5 were ordered from Sigma. The best result for knockdown was obtained from clone 49. The shRNA clone 48 sequence is, CCGGAGTGCAGAATTGGTT-TAAGATCTCGAGATCTTAAACCAATTCTG-CACTTTTTTG. The shRNA clone 49 sequence is, CCGGCAGCGCACTAATTCCTTTGATCTCGAGAT-CAAAGGAATTAGTGCGCTGTTTTTG). A lentivirus with the corresponding empty plasmid vector (CTV) was used as non-target control. Lentivirus with Rhox5 target and non target shRNA was used to infect CT26 cells at MOI of 1.0. After three rounds of puromycin (6.0 μg/ml) selection, stably transduced CT26 cells were selected and Rhox5 knockdown was assessed by both real-time RT-PCR and Western blot analysis.
Cell proliferation and cell migration assays
For cell proliferation assays, 1,000 CT26 cancer cells in 10% FBS-containing DMEM medium were added to each well of a 96-well plate. Cell proliferation was determined by using CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay Kit (Promega, Madison, WI). The reagent was added directly to culture wells, and following incubation for 4 h at 37°C, absorbance at 490 nm was measured using a 96-well plate reader. For trans-well migration assays, 1 × 10 5 serum starved cells in serum-free medium were added to the top chambers of 24-well trans-well plates (Cell Biolabs, San Diego, CA), and growth media containing 10% FBS was added to the bottom chambers. After 12 h of incubation, migrating cells were stained, and absorbance was recorded at 560 nm. Assays were done in triplicates, and the data are presented as the average absorbance of cells.
In vivo tumor growth
Athymic nude mice were ordered from Tacomic Farms, Inc. (Germantown, NY). Mice were housed in standard conditions and given food and water ad libitum . The animal study was approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh.
Rhox5 and control shRNA lentivirus-stably-transduced CT26 colon cancer cells were injected subcutaneously into hind frank of 5-6 weeks old athymic nude mice (1.0E5 cells per mouse, 5 mice per group). Mice were closely monitored until any one animal possessed a tumor of 2.0 centimeter in diameter. At this time point, tumor volumes of all mice were measured, and mice were sacrificed.
Statistical analysis
Statistical analysis was calculated using Microsoft Excel or SPSS software. Significance was calculated using Student's t -test.
